Multiply Relapsed HCL Patients:
If you're a multiply relapsed HCL patient looking for a non-chemotherapy treatment, consider the Moxe clinical trial at NIH. This is a Phase 3 trial.
Results from the Phase 1 trial indicate there is no toxicity, a complete remission rate of 57%, and a majority of those patients were able to eliminate all signs of malignancy. These results are superior to many other non-chemotherapy treatments for relapsed HCL. Check out the webpage or call Dr. Kreitman at 301-648-7375.
Here's a great link for patients that explains the trial and how the drug works.
"Moxetumomab is a nonchemotherapy treatment that can produce MRD-negative complete remissions where patients have a chance to be free of disease for a long duration," he explained. "We have patients who have been free of MRD for more than 5 years now on moxetumomab, and more than 10 years on the parent drug, BL22."
Here's a link to the clinical trial protocol details.
This referral letter explains the trial to doctors looking for treatment options for their multiply relapsed and refractory HCL patients.
If you're a multiply relapsed HCL patient looking for a non-chemotherapy treatment, consider the Moxe clinical trial at NIH. This is a Phase 3 trial.
Results from the Phase 1 trial indicate there is no toxicity, a complete remission rate of 57%, and a majority of those patients were able to eliminate all signs of malignancy. These results are superior to many other non-chemotherapy treatments for relapsed HCL. Check out the webpage or call Dr. Kreitman at 301-648-7375.
Here's a great link for patients that explains the trial and how the drug works.
"Moxetumomab is a nonchemotherapy treatment that can produce MRD-negative complete remissions where patients have a chance to be free of disease for a long duration," he explained. "We have patients who have been free of MRD for more than 5 years now on moxetumomab, and more than 10 years on the parent drug, BL22."
Here's a link to the clinical trial protocol details.
This referral letter explains the trial to doctors looking for treatment options for their multiply relapsed and refractory HCL patients.
